ADMA Biologics (NASDAQ:ADMA) Shares Up 4.6% – Here’s Why

ADMA Biologics Inc (NASDAQ:ADMA)’s share price rose 4.6% on Monday. The stock traded as high as $9.74 and last traded at $9.8090. Approximately 992,204 shares traded hands during mid-day trading, a decline of 77% from the average daily volume of 4,236,085 shares. The stock had previously closed at $9.38.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on ADMA shares. Weiss Ratings restated a “hold (c)” rating on shares of ADMA Biologics in a report on Monday, September 14th. Zacks Research raised ADMA Biologics from a “strong sell” rating to a “hold” rating in a report on Wednesday, September 2nd. Raymond James Financial assumed coverage on ADMA Biologics in a research note on Wednesday, June 10th. They issued an “outperform” rating and a $21.00 price target for the company. Finally, Mizuho decreased their price objective on ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating on the stock in a report on Wednesday, July 15th. Three equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $18.67.

ADMA Biologics Trading Up 7.8%

The company has a debt-to-equity ratio of 0.49, a current ratio of 6.97 and a quick ratio of 3.81. The business’s 50-day moving average price is $9.28 and its two-hundred day moving average price is $9.57. The company has a market capitalization of $2.26 billion, a price-to-earnings ratio of 14.51 and a beta of 0.78.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.16. The business had revenue of $124.39 million for the quarter, compared to the consensus estimate of $125.34 million. ADMA Biologics had a return on equity of 40.17% and a net margin of 32.98%.The firm’s quarterly revenue was up 2.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.14 earnings per share. Research analysts predict that ADMA Biologics Inc will post 0.78 earnings per share for the current year.

Institutional Investors Weigh In On ADMA Biologics

A number of large investors have recently bought and sold shares of ADMA. Royal Bank of Canada lifted its holdings in shares of ADMA Biologics by 448.8% during the 1st quarter. Royal Bank of Canada now owns 929,326 shares of the biotechnology company’s stock worth $8,373,000 after acquiring an additional 759,984 shares during the period. Bank of America Corp DE lifted its stake in ADMA Biologics by 107.5% during the first quarter. Bank of America Corp DE now owns 3,997,675 shares of the biotechnology company’s stock worth $36,019,000 after purchasing an additional 2,071,338 shares during the last quarter. Louisiana State Employees Retirement System acquired a new stake in shares of ADMA Biologics in the 1st quarter valued at $951,000. BNP Paribas Financial Markets increased its stake in shares of ADMA Biologics by 2,188.4% in the 4th quarter. BNP Paribas Financial Markets now owns 1,141,106 shares of the biotechnology company’s stock valued at $20,814,000 after purchasing an additional 1,091,241 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd raised its holdings in shares of ADMA Biologics by 1,508.1% during the 1st quarter. Y Intercept Hong Kong Ltd now owns 1,075,422 shares of the biotechnology company’s stock worth $9,690,000 after buying an additional 1,008,548 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company focused on developing, manufacturing and marketing plasma-derived biologic products for patients with compromised or inadequate immune systems. The company’s activities include operating plasma collection centers, sourcing human plasma, and producing specialized immunoglobulin therapies.

ADMA’s marketed products include ASCENIV, an intravenous immune globulin indicated for the treatment of primary humoral immunodeficiency disease; BIVIGAM, an intravenous immune globulin for primary humoral immunodeficiency; and Nabi-HB, a hepatitis B immune globulin used to provide protection against hepatitis B infection in certain clinical settings.